Compare Fox Corp Class A (FOXA) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs GSK plc — how do they compare? Fox Corp Class A trades at $62.41 (market cap $25.36B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.6× Fox Corp Class A's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and GSK plc for 93 Days on average.
| FOXA | GSK | |
|---|---|---|
Market Cap | $25.36B | $91.88B |
Volume | 2,566,954 | 7,730,529 |
Sector | Media | Health |
52-Week High | $76.11 | $61.18 |
52-Week Low | $48.79 | $43.24 |
Typical Hold Time | 34 Days | 93 Days |
Enterprise Value | $28.72B | $111.88B |
Dividend Yield | 0.91% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $63.57, up 1.39% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust 2025 results with revenue of $16.3B and net income of $2.26B, supported by solid cash flow. Analyst consensus is a Buy with a $72.00 price target, and recent news highlights the ongoing $22B Roku acquisition process and insider buying by CEO Lachlan Murdoch.
The outlook is positive given strong fundamentals and analyst support, but risks include regulatory scrutiny of the Roku deal and a projected net cash flow decline in 2026. The stock offers value with a P/E of 16.55 and growth potential, though investors must monitor deal approval and competitive pressures in media.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
